Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy

Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy

Abstract Background An unmet need remains for safe and effective treatments to induce and maintain remission in inflammatory bowel disease (IBD) patients. The Janus kinase (JAK) inhibitor, tofacitinib, has demonstrated robust efficacy in ulcerative colitis patients although, like other systemic immu...

Full description

Bibliographic Details
Main Authors: David T. Beattie, M. Teresa Pulido-Rios, Fei Shen, Melissa Ho, Eva Situ, Pam R. Tsuruda, Patrick Brassil, Melanie Kleinschek, Sharath Hegde
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Journal of Inflammation
Subjects:
Inflammatory bowel disease
Tofacitinib
Janus kinase inhibitor
Pharmacokinetics
Pharmacodynamics
Online Access:http://link.springer.com/article/10.1186/s12950-017-0175-2

Internet

http://link.springer.com/article/10.1186/s12950-017-0175-2

Similar Items